Trials / Completed
CompletedNCT00891371
Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study, is to assess the effect of lanreotide Autogel 120mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lanreotide (Autogel formulation) | Autogel 120mg |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2012-08-01
- Completion
- 2013-08-01
- First posted
- 2009-05-01
- Last updated
- 2019-01-15
- Results posted
- 2015-09-29
Locations
11 sites across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00891371. Inclusion in this directory is not an endorsement.